Cytomx Therapeutics, Inc. · NASDAQ:CTMX
Cytomx Therapeutics — ASCO 2020
15 slides from Cytomx Therapeutics's conference presentation, 2020
Slide 1: PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment
PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in Combination With Ipilimumab Thistlethwaite F,1* Naing A,2* Gil-Martin M,3 LoRusso P,4 Randhawa M,5 Eskens F,6 Sanborn R,7 Uboha N,8 Cho D,9
Slide 2: CX-072: An Anti-PD-L1 Probody Therapeutic Designed to Reduce Immune-related Adverse Events
CX-072: An Anti-PD-L1 Probody Therapeutic Designed to Reduce Immune-related Adverse Events • Probody therapeutics are recombinant antibody prodrugs designed to remain inactive in healthy ANTI-CANCER ANTIBODY tissue, and activated in the tumor microenvironment by tumor-associated PROTEASES LINKER pro
Slide 3: CX-072 Clinical Trial Design
CX-072 Clinical Trial Design CX-072 0.3 – 3 mg/kg • Phase 1: monotherapy q2w1-2 (n= 34) • CX-072 0.03 – 30 mg/kg (MTD was not reached) CX-072 Monotherapy CX-072 10 mg/kg • Phase 1: combination with ipilimumab (IPI)3-4 (n = 151) (n = 114) • MTD was CX-072 10 mg/kg + IPI 3 mg/kg CX-072 30 mg/kg • Phas
Slide 4: Activity Observed in IO-Responsive Tumors: CX-072 Monotherapy (10 mg/kg)
Activity Observed in IO-Responsive Tumors: CX-072 Monotherapy (10 mg/kg) Small Bowel # # UP UPS Sarcoma aSCC Anal SCC cSCC cScc TNBC TNBC with Skin Lsn hTMB hTMB Adenocarcinoma SBA Thymoma Thymoma 120 (%) 100 Baseline(%) 80 60 fromBaseline 40 20 0 -20 Burden from -40 -60 -80 TumorLesions -100 120 10
Slide 5: Activity Observed in Phase 1 Dose Escalation: Unselected Patients Treated with CX-072 + Ipilimumab
40 20 from Baseline (%) Activity Observed in Phase 1 Dose Escalation 0 -20 Unselected Patients Treated with CX-072 + Ipilimumab -40 -60 -80 Lesions -100 Tumor Type of Patients with Treatment Duration ≥ 6 months (%) 120 A: Uterine carcinoma (%) from Baseline (%) 120 Treatment: B: Salivary gland carci
Slide 6: CX-072 Chronic Administration: Tolerability
CX-072 Chronic Administration: Tolerability • CX-072 in the phase 1 trial performed as designed: • Circulating predominantly in the intact form1 • Activated in tumor tissues at high levels (with >98% receptor occupancy at doses of ≥ 3 mg/kg)1 • Demonstrated anticancer activity in both PD-1 sensitive
Slide 7: Demographics
Demographics Majority of patients enrolled had low or no tumor expression of PD-L1 CX-072 10 mg/kg CX-072 10 mg/kg CX-072 + IPI CX-072 + IPI < 6 months ≥ 6 months < 6 months ≥ 6 months (n=80) (n=34) (n=21) (n=6) Age – median (min, max) 59.5 (32, 83) 63.5 (32, 83) 56 (28, 70) 54.5 (39, 68) Sex – Male
Slide 8: Exposure
Exposure Long-term exposure to CX-072 was observed in both monotherapy and following combination treatment with ipilimumab CX-072 10 mg/kg CX-072 10 mg/kg CX-072 + IPI CX-072 + IPI < 6 months ≥ 6 months < 6 months ≥ 6 months (n=80) (n=34) (n=21) (n=6) Number of CX-072 Doses Administered, n (%) <=5 5
Slide 9: Adverse Event (AE) Overview
Adverse Event (AE) Overview Treatment related grade 3+ adverse event and immune-related adverse event rates were low CX-072 10 mg/kg CX-072 10 mg/kg CX-072 + IPI CX-072 + IPI < 6 months ≥ 6 months < 6 months ≥ 6 months (n=80) (n=34) (n=21) (n=6) Treatment-Emergent AE (TEAE), n (%) 78 (97.5) 33 (97.1
Slide 10: All Grade Treatment Related AE (>10% mono; >20% combo)
All Grade Treatment Related AE (>10% mono; >20% combo) CX-072 10 mg/kg CX-072 10 mg/kg CX-072 + IPI CX-072 + IPI < 6 months ≥ 6 months < 6 months ≥ 6 months (n=80) (n=34) (n=21) (n=6) Subjects with at least one Related TEAE, n (%) 36 (45.0) 30 (88.2) 17 (81.0) 6 (100.0) Fatigue 9 (11.3) 9 (26.5) 2 (
Slide 11: Treatment Related Grade 3+ AE (≥ 1 patient)
Treatment Related Grade 3+ AE (≥ 1 patient) Grade 3+ events were uncommon CX-072 10 mg/kg CX-072 10 mg/kg CX-072 + IPI CX-072 + IPI < 6 months ≥ 6 months < 6 months ≥ 6 months (n=80) (n=34) (n=21) (n=6) Subjects with at least one Related Grade 3+ TEAE, n (%) 8 (10.0) 2 (5.9) 7 (33.3) 2 (33.3) Coliti
Slide 12: Immune-related AE (≥ 2 patients or ≥ 1 patient for Grade 3+)
Immune-related AE (≥ 2 patients or ≥ 1 patient for Grade 3+) Rates were low across all groups and no Grade 3+ events were reported in long-term patients CX-072 10 mg/kg CX-072 10 mg/kg CX-072 + IPI CX-072 + IPI < 6 months ≥ 6 months < 6 months ≥ 6 months (n=80) (n=34) (n=21) (n=6) All Grade Grade 3+
Slide 13: Conclusions
Conclusions • Consistent with other checkpoint inhibitors, CX-072 showed highly durable objective responses • CX-072 was well tolerated alone or in combination with ipilimumab administered at doses ≥3 mg/kg • irAEs including pneumonitis, hepatitis, colitis, rash, and endocrinopathies were infrequent
Slide 14: Acknowledgements
Acknowledgements • We would like to extend our grateful thanks to our co-investigators, their research personnel, and colleagues at CytomX Therapeutics and MedPace. • Our sincere thanks to all patients and their caregivers who took part in this clinical trial. 14 Fiona Thistlethwaite
Slide 15: Acknowledgements
Acknowledgements Hendrik-Tobias Arkenau Sarah Cannon Research Institute UK Limited Javier Lavernia Instituto Valenciano De Oncologia Karen Autio Memorial Sloan Kettering Cancer Center Patricia LoRusso Yale University School of Medicine - Yale Cancer Center Johanna Bendell Sarah Cannon Research Insti